Norepinephrine Noridem (Noradrenaline Tartrate)

Noradrenaline tartrate directly stimulates alpha‑1 adrenergic receptors causing vasoconstriction and beta‑1 receptors in the heart, which increase heart rate and contractility. This dual action raises systemic vascular resistance and cardiac output, quickly correcting low arterial pressure.

The dose of Norepinephrine Noridem is individualized. A qualified prescriber determines the infusion rate based on the patient’s blood pressure response, clinical condition, and therapeutic goals, following local guidelines and monitoring protocols.

Safety data for Norepinephrine Noridem in pregnancy or lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Norepinephrine is often preferred for its balanced alpha‑1 and beta‑1 activity, providing both vasoconstriction and modest cardiac stimulation. Compared with pure alpha agonists like phenylephrine, it better supports cardiac output, while it may cause fewer tachyarrhythmias than dopamine in similar settings.

The product should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use and discard any solution that appears discolored or contains particles.

Norepinephrine Noridem is supplied as an injectable solution for intravenous infusion. It is typically administered through a controlled infusion pump, often via a central venous catheter, with continuous blood pressure monitoring to titrate the dose.

Serious risks include severe hypertension, myocardial ischemia or infarction, life‑threatening arrhythmias, tissue necrosis from extravasation, and pulmonary edema. Prompt recognition and management of these events are critical.

Patients with known hypersensitivity to noradrenaline or any formulation component should avoid it. It is also contraindicated in uncontrolled hypertension and should be used with extreme caution in patients with severe peripheral vascular disease or recent myocardial infarction.